Summary
This article presents the 10-year results of a study comparing taxane type and schedule as a component of adjuvant chemotherapy in localized breast cancer. When administered after doxorubicin-cyclophosphamide, weekly paclitaxel and every-3-weeks docetaxel significantly improved outcomes in the entire study population, while weekly paclitaxel improved outcomes in triple-negative breast cancer.
- adjuvant therapy
- combination treatment
- axillary node positive
- disease-free survival
- doxorubicin
- cyclophosphamide
- paclitaxel
- A Phase 3 Study of Doxorubicin-Cyclophosphamide Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer
- E1199
- BC
- NCT00004125
- © 2014 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.